Oric Pharmaceuticals Income Statement (2019-2026) | ORIC

Income Statement Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Operating items
Research & Development (Quarter)
15.52M12.90M16.75M16.83M13.83M14.72M16.30M19.52M18.79M22.39M24.48M21.96M28.94M31.20M31.97M24.64M30.55M28.77M25.86M31.44M
Selling, General & Administrative (Quarter)
5.54M5.56M6.06M6.43M6.86M5.97M5.82M6.16M6.21M6.29M6.95M7.03M7.08M7.12M7.60M8.08M8.52M7.90M8.70M8.18M
Other Operating Expenses (Quarter)
5.00M
Operating Expenses (Quarter)
21.06M18.46M22.80M23.26M20.70M25.69M22.12M25.68M24.99M28.68M31.43M28.99M36.02M38.32M39.57M32.72M39.06M36.67M34.55M39.62M
Operating Income (Quarter)
-21.06M-18.46M-22.80M-23.26M-20.70M-25.69M-22.12M-25.68M-24.99M-28.68M-31.43M-28.99M-36.02M-38.32M-39.57M-32.72M-39.06M-36.67M-34.55M-39.62M
EBIT (Quarter)
-21.06M-18.46M-22.80M-23.26M-20.70M-25.69M-22.12M-25.68M-24.99M-28.68M-31.43M-28.99M-36.02M-38.32M-39.57M-32.72M-39.06M-36.67M-34.55M-39.62M
Non-operating items
Interest & Investment Income (Quarter)
0.01M0.03M0.03M0.10M1.27M1.73M
Other Non Operating Income (Quarter)
0.01M
Non Operating Income (Quarter)
0.05M0.03M0.03M0.10M0.41M0.86M1.27M1.73M2.05M3.20M3.10M3.98M4.05M3.75M3.26M2.70M2.71M4.08M4.05M3.85M
Net income details
EBT (Quarter)
-21.04M-18.43M-22.77M-23.16M-20.70M-25.69M-20.85M-23.95M-24.99M-28.68M-31.43M-28.99M-36.02M-38.32M-39.57M-32.72M-39.06M-36.67M-34.55M-39.62M
Profit After Tax (Quarter)
-21.01M-18.43M-22.77M-23.16M-20.29M-24.83M-20.85M-23.95M-22.94M-25.48M-28.33M-25.01M-31.96M-34.57M-36.31M-30.02M-36.35M-32.59M-30.50M-35.77M
Income from Continuing Operations (Quarter)
-21.04M-18.43M-22.77M-23.16M-20.70M-25.69M-20.85M-23.95M-24.99M-28.68M-31.43M-28.99M-36.02M-38.32M-39.57M-32.72M-39.06M-36.67M-34.55M-39.62M
Consolidated Net Income (Quarter)
-21.04M-18.43M-22.77M-23.16M-20.70M-25.69M-20.85M-23.95M-24.99M-28.68M-31.43M-28.99M-36.02M-38.32M-39.57M-32.72M-39.06M-36.67M-34.55M-39.62M
Income towards Parent Company (Quarter)
-21.04M-18.43M-22.77M-23.16M-20.70M-25.69M-20.85M-23.95M-24.99M-28.68M-31.43M-28.99M-36.02M-38.32M-39.57M-32.72M-39.06M-36.67M-34.55M-39.62M
Net Income towards Common Stockholders (Quarter)
-21.04M-18.43M-22.77M-23.16M-20.70M-25.69M-20.85M-23.95M-24.99M-28.68M-31.43M-28.99M-36.02M-38.32M-39.57M-32.72M-39.06M-36.67M-34.55M-39.62M
Additional items
EPS (Basic) (Quarter)
-0.57-0.47-0.58-0.59-0.51-0.63-0.52-0.53-0.50-0.44-0.50-0.37-0.45-0.49-0.51-0.42-0.47-0.33-0.27-0.34
EPS (Weighted Average and Diluted) (Quarter)
-0.57-0.47-0.58-0.59-0.51-0.63-0.52-0.53-0.50-0.44-0.50-0.37-0.45-0.49-0.51-0.42-0.47-0.33-0.27-0.34
Shares Outstanding (Weighted Average) (Quarter)
36.69M39.01M37.95M39.43M39.48M39.58M39.66M45.09M45.65M57.40M51.45M67.35M68.85M70.54M69.73M71.04M74.60M98.95M87.79M105.47M
Shares Outstanding (Diluted Average) (Quarter)
36.69M39.01M37.95M39.43M39.46M39.58M39.66M45.09M45.65M57.40M51.45M67.35M68.85M69.42M69.73M71.04M74.60M82.81M87.79M105.47M
EBITDA (Quarter)
-21.02M-18.43M-22.87M-23.86M-20.72M-25.34M-20.39M-23.15M-23.01M-25.28M-27.70M-25.43M-32.06M-33.59M-36.65M-30.19M-36.38M-32.16M-30.33M-36.84M